Dr. Kreider is the Co- Director of the Interstitial Lung
Disease Program and has expertise in the evaluation and
treatment of patients with diffuse parenchymal lung diseases.
Additionally, she is the Medical Director of the Pulmonary
Diagnostics Laboratory of the Hospital of the University
of Pennsylvania. Dr. Kreider’s clinical interests
include patients with Idiopathic Pulmonary Fibrosis, Pulmonary
Fibrosis associated with Collagen Vascular Disease, Chronic
Hypersensitivity Pneumonitis and Sarcoidosis. She also maintains
a general pulmonary practice and sees a broad range of pulmonary
disease patients. A recipient of a Masters degree in Clinical
Epidemiology and Biostatistics, Dr. Kreider studies risk
factors for both the development of Interstitial Lung Diseases
and for poor outcome. She is an active participant in several
drug trials for patients both with pulmonary fibrosis and
sarcoidosis.
Kreider ME, Grippi M Impact of the New ATS/ERS Pulmonary
Function Test Interpretation Guidelines, Respiratory Medicien
(in press).
Kreider ME, Hansen-Flaschen J, Ahmad N, Rossman MD, Kaiser
L, Kucharczuk J, Shrager J. Complications of Video- Assisted
Thoracoscopic Lung Biopsy in Patients with Interstitial
Lung Disease. Annals of Thoracic Surgery, 83:1140-4 (2007).
Kreider ME, Rossman MD Lessons Learned From ACCESS (A Case
Controlled Etiologic Study of Sarcoidosis). Proceedings
of the American Thoracic Society. (in press)
Kreider ME, Christie J, Thompson B, Newman LS, Rose C, Barnard
JA, Bresnitz E, Judson MA, Lackland D, and Rossman M. Environmental
exposures and the clinical phenotype of sarcoidosis. Chest,
128:207-15 (2005).
Kreider ME, Rossman, MD. HLA and Sarcoidosis. Sarcoidosis,
Volume 210, Lung Biology in Health and Disease, Taylor and
Francis, New York, 2006.
Kreider ME, Rossman MD. Pulmonary Tuberculosis. Tuberculosis
and Nontuberculosis Mycobacterial Infections. , 5th edition,
McGraw Hill Press, New York, 2006.
reviseed 7/07
